Significance of 18F-Fluorodeoxyglucose (FDG) Uptake in Response to Chemoradiotherapy for Pancreatic Cancer

[1]  T. Arisawa,et al.  Use of count-based image reconstruction to evaluate the variability and repeatability of measured standardised uptake values , 2018, PloS one.

[2]  S. Natsugoe,et al.  Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma , 2018, Annals of surgical oncology.

[3]  F. Motoi,et al.  18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma , 2018, Journal of Gastrointestinal Surgery.

[4]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, The Journal of the National Comprehensive Cancer Network.

[5]  M. Partridge,et al.  Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  T. Strom,et al.  Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy , 2017, Acta oncologica.

[7]  S. Shiraishi,et al.  Preoperative High Maximum Standardized Uptake Value in Association with Glucose Transporter 1 Predicts Poor Prognosis in Pancreatic Cancer , 2017, Annals of Surgical Oncology.

[8]  Yonghong Shi,et al.  Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients , 2017, Oncotarget.

[9]  C. Lyssiotis,et al.  Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer. , 2017, Cancer cell.

[10]  M. Yano,et al.  Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence , 2016, Annals of surgery.

[11]  M. Büchler,et al.  Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer , 2016, The British journal of surgery.

[12]  T. Murakami,et al.  The correlation between FDG uptake and biological molecular markers in pancreatic cancer patients. , 2016, European journal of radiology.

[13]  M. Malafa,et al.  Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma , 2016, Pancreas.

[14]  David Goldstein,et al.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. , 2016, JAMA.

[15]  R. Korn,et al.  Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas† , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Shuihong Zhou,et al.  Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo , 2015, PloS one.

[17]  J. Long,et al.  Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. , 2015, Cancer letters.

[18]  Xianjun Yu,et al.  Role of SUVmax obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation , 2013, Nuclear medicine communications.

[19]  J. Bussink,et al.  Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy , 2012, Clinical Cancer Research.

[20]  S. Natsugoe,et al.  A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer , 2012, Journal of hepato-biliary-pancreatic sciences.

[21]  H. Eguchi,et al.  Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer , 2012, Annals of surgery.

[22]  D. Bentrem,et al.  Apigenin down-regulates the hypoxia response genes: HIF-1α, GLUT-1, and VEGF in human pancreatic cancer cells. , 2011, The Journal of surgical research.

[23]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: What Have We Learned and Where Do We Go From Here? , 2011, Annals of Surgical Oncology.

[24]  A. Levine,et al.  The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.

[25]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[26]  S. Natsugoe,et al.  Comparison of hyper-fractionated accelerated and standard fractionated radiotherapy with concomitant low-dose gemcitabine for unresectable pancreatic cancer. , 2008, Anticancer research.

[27]  J. Berlin,et al.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Hoskin,et al.  Positron emission tomography in oncology: a review. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[29]  Eric J. W. Visser,et al.  Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  S. Jinnouchi,et al.  Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. , 2006, Journal of hepato-biliary-pancreatic surgery.

[31]  E. Paulson,et al.  Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer , 2005, Annals of Surgical Oncology.

[32]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[33]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[35]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[36]  H. Minn,et al.  F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic Cancer , 2009 .